A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Phase of Trial: Phase III
Latest Information Update: 14 Oct 2017
At a glance
- Drugs IMA 901 (Primary) ; Sunitinib (Primary) ; Cyclophosphamide
- Indications Renal cancer; Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms IMPRINT
- Sponsors immatics biotechnologies GmbH
- 10 Jun 2017 Biomarkers information updated
- 03 Oct 2016 Efficacy and safety results (n=339) published in the Lancet Oncology.
- 17 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.